Previous Close | 2.7300 |
Open | 2.6300 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 800 |
Day's Range | 2.4563 - 2.6600 |
52 Week Range | 0.1700 - 12.4500 |
Volume | |
Avg. Volume | 458,114 |
Market Cap | 8.255M |
Beta (5Y Monthly) | -0.76 |
PE Ratio (TTM) | 0.80 |
EPS (TTM) | 3.2700 |
Earnings Date | Nov 11, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SILO
ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in compliance w
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco
SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous a